4-Functionally-Substituted 3-Heterylpyrazoles: XIX.* 3-Aryl-4-(5-Isoxazolyl)pyrazoles

M. K. Bratenko^a, Yu. V. Kadel'nik^a, V. A. Chornous^a, and M. V. Vovk^b

^aBukovina State Medical University, Chernovtsy, Ukraine ^bInstitute of Organic Chemistry, National Academy of Sciences of Ukraine, Kiev, 02094 Ukraine e-mail: chornous@inbox.ru

Received April 10, 2007

Abstract—Oximes of 4-(4-pyrazolyl)-3-buten-2-onees obtained by successive reaction of 3-aryl-4-formylpyrazoles with acetone and hydroxylamine at the treatment with iodine suffered an oxidative cyclization yielding 3-aryl-4-(5-isoxazolyl)pyrazoles.

DOI: 10.1134/S1070428008020103

The designing of new types of polyheterocyclic compounds alongside the refining of procedures for preparation of these known substances is an urgent target of the modern heterocyclic chemistry. Many among the heterocyclic ensembles are both convenient models for investigating the interaction of heterofragments and structures with potential high biological activity. The analysis of published data shows the high promise of purposeful synthetic search in the series of heteryl-substituted pyrazoles. In particular, pyrazole derivatives already were formerly obtained containing in the position 4 oxazoline [2], dihydropyridine [3], pyrazoline [4, 5], dihydropyrimidine [6], and benzopyran [7] fragments.

Here we report on investigation results on the synthesis of new pyrazole derivatives functionalized in the position 4 with pharmacologically significant [8] isoxazole ring. The information on similar compounds is limited to [9, 10] where the building up of pyrazole or isoxazole rings respectively occurs based on relatively difficultly available isoxazolyl- or pyrazolyl- β -diketones. The condensation of more accessible β -(1,3-diphenyl-pyrazolyl)- α -ethyl vinyl ketone with hydroxylamine however provided only 4-(4,5-dihydroisoxazolyl)-1,5-diphenylpyrazole [4].

We found that β -(1,3-diphenylpyrazolyl)- α -ethyl vinyl ketones **Ia–If** obtained by condensation of 3-aryl-4-formylpyrazoles **IIa–IIf** with acetone in reaction with hydroxylamine hydrochloride in boiling pyridine did not form a 4,5-dihydroisoxazole ring but give stable oximes

IIIa–IIIf. Analysis of ¹H NMR spectra of α , β -vinyl ketones **Ia–If** indicted that they existed exclusively in the form of *E*-isomers. Yet their oximes formed as *E*,*Z*- and *E*,*E*-isomers, the fact previously unknown for 4-aryl-3-buten-2-ones [11–13]. This fact is proved by a double set of signals from protons H⁵ of the pyrazole ring and from groups CH₃ and OH. Taking into account the data of [11, 12] it is possible to assume reliably that in the case in question prevailingly form *E*,*Z*-isomers more stereochemically favorable for further cyclization: The content of these isomers varies in the range 81–85%. The preferable procedure for conversion of oximes **IIIa–IIIf** into target 4-(5-isoxazolyl)pyrazoles **IVa–IVf**



Ar = Ph (**a**), 4-FC₆H₄(**b**), 4-ClC₆H₄(**c**), 4-MeC₆H₄(**d**), 4-EtC₆H₄(**e**), 4-MeOC₆H₄(**f**).

^{*} For communication XVIII, see [1].

proved to be the oxidative cyclization by means of iodine [13]. The application of a system I_2 -KI-NaHCO₃ in boiling DMF made it possible to obtain compounds **IVa**-**IVf** in 58–71% yields.

The structure of 4-isoxazolopyrazoles IV was confirmed by ¹H NMR spectra where along with typical signals of aromatic and methyl substituents were observed the singlet of proton H⁴ from the isoxazole ring (6.19–6.29 ppm) and proton H⁵ of the pyrazole ring (8.90–9.11 ppm).

EXPERIMENTAL

IR spectra of compounds were recorded on a spectrophotometer UR-20 from KBr pellets. ¹H NMR spectra were registered on a spectrometer Varian-Gemini (300 MHz) in $(CD_3)_2SO$, internal referece TMS.

4-(4-Pyrazolyl)-3-buten-2-ones Ia–If. To a solution of 40 mmol of aldehyde **IIa–IIf** in 50 ml of acetone was added at stirring 5 ml of 10% water solution of NaOH, the mixture was stirred at room temperature for 12 h, then into the reaction mixture 200 ml of ice water was poured. The separated precipitate was filtered off, washed with dilute hydrochloric acid, dried, and recrystallized from ethanol.

4-(1,3-Diphenyl-4-pyrazolyl)-3-buten-2-one (Ia). Yield 73%, mp 124–126°C. IR spectrum, cm⁻¹: 1665 (C=O). ¹H NMR spectrum, δ , ppm: 2.26 s (3H, CH₃), 6.71 d (1H, H², *J* 16.0 Hz), 7.05–7.64 m (11H, H_{arom}+H¹), 9.17 s (1H, H⁵_{pyrazole}). Found, %: C 78.89; H 5.67; N 9.60. C₁₉H₁₆N₂O. Calculated, %: C 79.16; H 5.56; N 9.72.

4-[1-Phenyl-3-(4-fluorophenyl)-4-pyrazolyl]-3buten-2-one (Ib). Yield 81%, mp 142–143°C. IR spectrum, cm⁻¹: 1665 (C=O). ¹H NMR spectrum, δ, ppm: 2.27 s (3H, CH₃), 6.73 d (1H, H², *J* 16.2 Hz), 7.29– 7.93 m (10H, 9H_{arom}+H¹), 9.16 s (1H, H⁵_{pyrazole}). Found, %: C 74.23; H 5.03; N 9.02. C₁₉H₁₅FN₂O. Calculated, %: C 74.51; H 4.90; N 9.15.

4-[1-Phenyl-3-(4-chlorophenyl)-4-pyrazolyl]-3buten-2-one (Ic). Yield 78%, mp 139–141°C. IR spectrum, cm⁻¹: 1670 (C=O). ¹H NMR spectrum, δ , ppm: 2.28 s (3H, CH₃), 6.73 d (1H, H², J 16.2 Hz), 7.32– 7.56 m (6H, 5H_{arom}+H¹), 7.68 d (2H, H_{arom}, J 8.4 Hz), 7.91 d (2H_{arom}, J 8.2 Hz), 9.16 s (1H, H⁵_{pyrazole}). Found, %: C 70.48; H 4.61; N 8.57. C₁₉H₁₅ClN₂O. Calculated, %: C 70.70; H 4.65; N 8.68.

4-[3-(4-Tolyl)-1-phenyl-4-pyrazolyl]-3-buten-2one (Id). Yield 76%, mp 140–142°C. IR spectrum, cm⁻¹: 1660 (C=O). ¹H NMR spectrum, δ, ppm: 2.22 s (3H, CH₃), 2.27 C (3H, CH₃), 6.74 d (1H, H², *J* 16.2 Hz), 7.32–7.53 m (6H, 5H_{arom}+H¹), 7.63 d (2H_{arom}, *J* 8.2 Hz), 7.92 d (2H_{arom}, *J* 7.8 Hz), 9.16 s (1H, H⁵_{pyrazole}). Found, %: C 79.42; H 6.09; N 9.13. C₂₀H₁₈N₂O. Calculated, %: C 79.47; H 5.96; N 9.27.

4-[1-Phenyl-3-(4-ethyl)-4-pyrazolyl]-3-buten-2one (Ie). Yield 72%, mp 119–120°C. IR spectrum, cm⁻¹: 1665 (C=O). ¹H NMR spectrum, δ , ppm: 1.27 t (3H, CH₃, *J* 7.5 Hz), 2.27 s (3H, CH₃), 2.70 q (2H, CH₂, *J* 7.5 Hz), 6.73 d (1H, H², *J* 16.5 Hz), 7.27–7.54 m (8H, 7H_{arom}+H¹), 7.92 d (2H_{arom}), 9.16 s (1H, H⁵_{pyrazole}). Found, %: C 80.04; H 6.29; N 8.95. C₂₁H₂₀N₂O. Calculated, %: C 79.75; H 6.33; N 8.86.

4-[3-(4-Methoxyphenyl)-1-phenyl-4-pyrazolyl]-3buten-2-one (If). Yield 71%, mp 135–136°C. IR spectrum, cm⁻¹: 1660 (C=O). ¹H NMR spectrum, δ , ppm: 2.26 s (3H, CH₃), 3.84 C (3H, CH₃O), 6.72 d (1H, H², *J* 16.2 Hz), 7.05 d (2H_{arom}, *J* 8.8 Hz), 7.35–7.56 m (6H, 5H_{arom}+H¹), 7.91 d (2H, H_{arom}, *J* 8.8 Hz), 9.12 s (1H, H⁵_{pyrazole}). Found, %: C 75.32; H 5.76; N 8.64. C₂₀H₁₈N₂O₂. Calculated, %: C 75.47; H 5.66; N 8.81.

4-(4-Pyrazolyl)-3-buten-2-ones oximes IIIa–IIIf. To a solution of 10 mmol of vinyl ketone **Ia–If** in 20 ml of pyridine was added 1.39 g (20 mmol) of hydroxylamine hydrochloride, and the mixture was boiled at reflux for 3 h. On cooling to room temperature the reaction mixture was poured into 100 ml of ice water, the separated precipitate was filtered off, washed with 10% hydrochloric acid, dried, and crystallized from ethanol.

4-(1,3-Diphenyl-4-pyrazolyl)-3-buten-2-one oxime (IIIa). Yield 83%, mp 150–152°C. IR spectrum, cm⁻¹: 1630 (C=N), 3280 (OH). ¹H NMR spectrum, δ , ppm: 1.95 s, 1.99 s (3H, CH₃), 6.72 d (1H, =CH_A, J 15.5 Hz), 6.79 d (1H, =CH_B, J 15.5 Hz), 7.30–7.51 m (6H_{arom}), 7.65 d (2H_{arom}, J 6.9 Hz), 7.91 d (2H_{arom}, J 7.1 Hz), 8.94 s, 9.01 s (1H, H⁵_{pyrazole}), 10.08 s, 10.96 s (1H, OH). Found, %: C 75.49; H 5.44; N 14.05. C₁₇H₁₇N₃O. Calculated, %: C 75.25; H 5.61; N 13.86.

4-[1-Phenyl-3-(4-fluorophenyl)-4-pyrazolyl]-3buten-2-one oxime (IIIb). Yield 85%, mp 224–226°C. IR spectrum, cm⁻¹: 1625 (C=N), 3285 (OH). ¹H NMR spectrum, δ , ppm: 1.93 s, 1.98 s (3H, CH₃), 6.70 d (1H, =CH_A, J 15.6 Hz), 6.77 d (1H, =CH_B, J 15.6 Hz), 7.25– 7.90 m (9H_{arom}), 8.92 s, 8.98 s (1H, H⁵_{pyrazole}), 10.64 s, 10.78 s (1H, OH). Found, %: C 70.77; H 5.14; N 13.32. C₁₉H₁₆FN₃O. Calculated, %: C 71.03; H 4.98; N 13.08.

4-[1-Phenyl-3-(4-chlorophenyl)-4-pyrazolyl]-3buten-2-one oxime (IIIc). Yield 87%, mp 248–250°C. IR spectrum, cm⁻¹: 1625 (C=N), 3290 (OH). ¹H NMR spectrum, δ , ppm: 1.95 s, 1.99 s (3H, CH₃), 6.74 d (1H, =CH_A, J 15.6 Hz), 6.80 d (1H, =CH_B, J 15.6 Hz), 7.29– 7.97 m (9H_{arom}), 8.93 s, 9.01 s (1H, H⁵_{pyrazole}), 10.68 s, 10.95 s (1H, OH). Found, %: C 67.82; H 4.85; N 12.59. C₁₉H₁₆ClN₃O. Calculated, %: C 67.56; H 4.74; N 12.44.

4-[3-(4-Tolylphenyl)-1-phenyl-4-pyrazolyl]-3buten-2-one oxime (IIId). Yield 78%, mp 223–225°C. IR spectrum, cm⁻¹: 1630 (C=N), 3280 (OH). ¹H NMR spectrum, δ , ppm: 1.94 s, 1.98 s (3H, CH₃), 6.73 d (1H, =CH_A, J 15.5 Hz), 6.81 d (1H, =CH_B, J 15.5 Hz), 7.31– 7.88 m (9H_{arom}), 8.91 s, 8.99 s (1H, H⁵_{pyrazole}), 10.72 s, 10.94 s (1H, OH). Found, %: C 75.79; H 6.05; N 13.29. C₂₀H₁₉N₃O. Calculated, %: C 75.71; H 5.99; N 13.25.

4-[1-Phenyl-3-(4-ethylphenyl)-4-pyrazolyl]-3buten-2-one oxime (IIIe). Yield 81%, mp 175–176°C. IR spectrum, cm⁻¹: 1630(C=N), 3280 (OH). ¹H NMR spectrum, δ , ppm: 1.27 t (3H, CH₃, *J* 7.5 Hz), 1.95 s, 1.99 s (3H, CH₃), 2.68 d (2H, CH₂, *J* 7.5 Hz), 6.77 d (1H, =CH_A, *J* 15.5 Hz), 6.84 d (1H, =CH_B, *J* 15.5 Hz), 7.28–7.94 m (9H_{arom}), 8.93 C, 9.01 s (1H, H⁵_{pyrazole}), 10.69 s, 10.95 s (1H, OH). Found, %: C 70.77; H 5.14; N 13.32. C₁₉H₁₆FN₃O. Calculated, %: C 71.03; H 4.98; N 13.08.

4-[3-(4-Methoxyphenyl)-1-phenyl-4-pyrazolyl]-3buten-2-one oxime (IIIf). Yield 77%, mp 192–194°C. IR spectrum, cm⁻¹: 1625 (C=N), 3275 (OH). ¹H NMR spectrum, δ , ppm: 1.95 s, 1.99 s (3H, CH₃), 3.83 s (3H, CH₃O) 6.73 d (1H, =CH_A, J 15.6 Hz), 6.80 d (1H, =CH_B, J 15.6 Hz), 7.02–7.94 m (9H_{arom}), 8.88 s, 8.96 s (1H, H⁵_{pyrazole}), 10.64 s, 10.91 s (1H, OH). Found, %: C 71.79; H 5.56; N 12.50. C₂₀H₁₉N₃O₂. Calculated, %: C 72.07; H 5.71; N 12.61.

3-Aryl-4-(5-isoxazolyl)pyrazoles IVa–IVf. To a solution of 3.3 mmol of oxime **IIIa–IIIf** in 15 ml of DMF was added a mixture of 0.85 g (3.3mmol) of iodine, 1.8 g (11 mmol) of potassium iodide, and 1 g (12 mmol) of sodium hydrogen carbonate in 5 ml of water, and the reaction mixture was boiled for 3 h. On cooling to room temperature the reaction mixture was poured into 100 ml of 2% solution of sodium thiosulfate, the separated precipitate was filtered off, washed with water, and crystallized from acetic acid.

4-(3-Methyl-5-isoxazolyl)-1,3-diphenylpyrazole (**IVa).** Yield 68%, mp 116–118°C. ¹H NMR spectrum, δ , ppm: 2.24 s (3H, CH₃), 6.17 s (1H, H⁴_{isoxazole}), 7.33– 7.61 m (8H_{arom}), 7.92 d (2H_{arom}, *J* 8.1 Hz), 9.06 s (1H, H⁵_{pyrazole}). Found, %: C 75.69; H 5.05; N 14.00. C₁₉H₁₅N₃O. Calculated, %: C 75.73; H 5.02; N 13.94. **4-(3-Methyl-5-isoxazolyl)-1-phenyl-3-(4-fluorophenyl)pyrazole (IVb).** Yield 67%, mp 136–137°C. ¹H NMR spectrum, δ , ppm: 2.25 s (3H, CH₃), 6.29 s (1H, H⁴_{isoxazole}), 7.33–7.67 m (7H_{arom}), 7.96 d (2H_{arom}, *J* 7.9 Hz), 9.11 s (1H, H⁵_{pyrazole}). Found, %: C 71.40; H 4.46; N 13.08. C₁₉H₁₄FN₃O. Calculated, %: C 71.46; H 4.42; N 13.16.

4-(3-Methyl-5-isoxazolyl)-1-phenyl-3-(4-chlorophenyl)pyrazole (IVc). Yield 63%, mp 135–136°C. ¹H NMR spectrum, δ , ppm: 2.26 s (3H, CH₃), 6.24 s (1H, H⁴_{isoxazole}), 7.36–7.66 m (7H_{arom}), 7.95 d (2H_{arom}, *J*8.0 Hz), 9.07 s (1H, H⁵_{pyrazole}). Found, %: C 71.40; H 4.46; N 13.08. C₁₉H₁₄ClN₃O. Calculated, %: C 67.96; H 4.20; N 12.51.

4-(3-Methyl-5-isoxazolyl)-3-(4-tolylphenyl)-1phenylpyrazole (IVd). Yield 71%, mp 142–143°C. ¹H NMR spectrum, δ , ppm: 2.24 s (3H, CH₃), 2.40 s (3H, CH₃), 6.20 s (1H, H⁴_{isoxazole}), 7.26–7.54 m (7H_{arom}), 7.41 d (2H_{arom}, *J* 7.2 Hz), 9.03 s (1H, H⁵_{pyrazole}). Found, %: C 76.23; H 5.35; N 13.38. C₂₀H₁₇N₃O. Calculated, %: C 76.17; H 5.43; N 13.32.

4-(3-Methyl-5-isoxazolyl)-1-phenyl-3-(4-ethyl-phenyl)pyrazole (IVe). Yield 58%, mp 139–140°C. ¹H NMR spectrum, δ , ppm: 1.27 t (3H, CH₃, *J* 7.5 Hz), 2.24 C (3H, CH₃), 2.71 q (2H, CH₂, *J* 7.5 Hz), 6.17 s (1H, H⁴_{isoxazole}), 7.31–7.52 m (7H_{arom}), 7.93 d (2H_{arom}, *J* 7.0 Hz), 9.03 s (1H, H⁵_{pyrazole}). Found, %: C 76.50; H 5.88; N 12.70. C₂₁H₁₉N₃O. Calculated, %: C 76.57; H 5.81; N 12.76.

4-(3-Methyl-5-isoxazolyl)-3-(4-methoxyphenyl)-1phenylpyrazole (IVf). Yield 63%, mp 129–130°C. ¹H NMR spectrum, δ , ppm: 2.24 s (3H, CH₃), 3.83 C (3H, CH₃O), 6.16 s (1H, H⁴_{isoxazole}), 7.01 d (2H_{arom}, *J* 6.9 Hz), 7.36–7.53 m (5H_{arom}), 7.92 d (2H_{arom}, *J* 6.9 Hz), 8.99 s (1H, H⁵_{pyrazole}). Found, %: C 72.40; H 5.27; N 12.63. C₂₀H₁₇N₃O₂. Calculated, %: C 72.49; H 5.17; N 12.68.

REFERENCES

- Bratenko, M.K., Chornous, V.O., and Vovk, M.V., *Zh. Org. Khim.*, 2007, vol. 43, p. 1213.
- 2. Elkashef, M.K.-F., Abdel-Magein, F.M.E., and Yassius, M.A., *Lieb. Ann.*, 1974, p. 37.
- 3. Chernyavichus, V.S., Odinets, A.G., Sausyn', A.E., Berzinya, A.Ya., and Zolotoyabko, R.M., *Khim.-Farm. Zh.*, 1987, vol. 21, p. 959.
- Chary, T.J.M., Reddy, Ch.V.N., and Nurthy, A.K., *Ind. J. Chem. B.*, 1992, vol. 31, p. 495.
- 5. Bratenko, M.K., Chornous, V.O., and Vovk, M.V., Zh. Org.

RUSSIAN JOURNAL OF ORGANIC CHEMISTRY Vol. 44 No. 2 2008

Khim., 2001, vol. 37, p. 591.

- 6. El-Emary, T.I. and Bakhite, E.A., *Pharmazie*, 1999, vol. 54, p. 106.
- 7. Kumar, K.H. and Perumal, P.T., Chem. Lett., 2005, vol. 34, p. 1346.
- 8. Mashkovskii, M.D., *Lekarstvennye sredstva* (Drugs), Moscow: Novaya volna, 2000, vol. 2, pp. 227, 282.
- 9. Eiden, F. and Patzelt, G., Arch. Pharm., 1986, vol. 319,

p. 242.

- 10. Bendaas, A., Homdi, M., and Selier, N., *J. Heterocycl. Chem.*, 1999, vol. 36, p. 1291.
- 11. Unterhalt, B. and Pindur, U., Arch. Pharm., 1973, vol. 306, p. 586.
- 12. Unterhalt, B., Arch. Pharm., 1978, vol. 311, p. 265.
- 13. Alberola, A., Banez, J.M., Carlo, L., Rodriguez, M.T., and Sanudo, M.C., *J. Heterocycl. Chem.*, 1993, vol. 30, p. 467.